Delinia, a Cambridge, Massachusetts-based new company developing novel therapeutics that rebalance the immune system to treat serious and life-threatening autoimmune diseases, closed a $35m Series A funding.
The round was co-led by Sofinnova Partners and Atlas Venture.
Led by CSO Jeffrey Greve, PhD, and President and CEO Saurabh Saha, MD, PhD, Venture Partner with Atlas Venture, Delinia is advancing a novel protein therapeutic platform which specifically targets, activates, and augments the levels of Tregs, a cell type that naturally exists in the body and whose role is to regulate the inflammatory response of other cells.
The company’s Scientific Advisory Board (SAB), chaired by co-founder Michael Rosenblum MD PhD, who serves as Assistant Professor of Dermatology at the UCSF School of Medicine, also includes:
– Abul Abbas MD, Distinguished Professor of Pathology and Chair of Pathology at the UCSF School of Medicine;
– Christophe Benoist MD PhD, Grove-Rasmussen Professor of Microbiology and Immunology at Harvard Medical School;
– Jerome Ritz MD, Professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, and Executive Director of the Connell O’Reilly Cell Manipulation and Gene Transfer Laboratory; and
– David Wofsy MD, Professor of Medicine and Microbiology/Immunology at the UCSF School of Medicine.
The board of Directors, chaired by Jeffrey Tong PhD, Entrepreneur in Residence at Third Rock Ventures, includes Henrijette Richter PhD, Partner at Sofinnova Partners, David Grayzel MD, Partner at Atlas Venture, and President and CEO Saurabh Saha MD PhD.
The company also has research operations in San Francisco, California.